Additional 44,000 Paxlovid Doses Imported Domestically on the 24th

Pfizer Vaccine 1,041,000 Doses Also Introduced

On January 14th, Paxlovid, an oral treatment for COVID-19, was delivered to a pharmacy in Guro-gu, Seoul. Photo by Jinhyung Kang aymsdream@

[Asia Economy Reporter Kim Young-won] On the 24th, an additional 44,000 doses of the oral COVID-19 treatment Paxlovid will be introduced into the country.

The Central Disease Control Headquarters (CDCH) announced on the 23rd the plan to import additional quantities of this oral treatment. As of the 22nd, a total of 102,000 doses of Paxlovid have been administered, and the stockpile stands at 61,000 doses. With the additional 44,000 doses, the total amount of Paxlovid introduced into the country will reach 207,000 doses. The health authorities have pre-purchased a total of 762,000 doses of Paxlovid.

Additionally, 1,041,000 doses of Pfizer's COVID-19 vaccine will be introduced into the country on the 24th. Including this additional supply, the cumulative vaccine supply in the country as of the 24th will be 14.96 million doses.

The government stated, "We will continue to closely coordinate with pharmaceutical companies to ensure a stable supply of vaccines," and added, "Specific supply schedules will be promptly announced after consultation."

Meanwhile, on the same day, the Korea Disease Control and Prevention Agency announced that it is reviewing a request to the Ministry of Food and Drug Safety for domestic approval of AstraZeneca (AZ)'s antibody treatment 'Evusheld.' Evusheld was approved by the U.S. FDA in December last year and by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) on the 17th of this month.

This content was produced with the assistance of AI translation services.